According to NICE draft guidance, clinical trial evidence suggests romosozumab followed by alendronic acid is more effective at reducing the risk of fractures than alendronic acid alone. But there is uncertainty because the population in the clinical trial is different to the proposed population.
You can consent to the use of such technologies by closing this notice.
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activities described below. To learn more about how these trackers help us